Your SlideShare is downloading. ×
0
Dr abdo oboud presentation ca cx prevention
Dr abdo oboud presentation ca cx prevention
Dr abdo oboud presentation ca cx prevention
Dr abdo oboud presentation ca cx prevention
Dr abdo oboud presentation ca cx prevention
Dr abdo oboud presentation ca cx prevention
Dr abdo oboud presentation ca cx prevention
Dr abdo oboud presentation ca cx prevention
Dr abdo oboud presentation ca cx prevention
Dr abdo oboud presentation ca cx prevention
Dr abdo oboud presentation ca cx prevention
Dr abdo oboud presentation ca cx prevention
Dr abdo oboud presentation ca cx prevention
Dr abdo oboud presentation ca cx prevention
Dr abdo oboud presentation ca cx prevention
Dr abdo oboud presentation ca cx prevention
Dr abdo oboud presentation ca cx prevention
Dr abdo oboud presentation ca cx prevention
Dr abdo oboud presentation ca cx prevention
Dr abdo oboud presentation ca cx prevention
Dr abdo oboud presentation ca cx prevention
Dr abdo oboud presentation ca cx prevention
Dr abdo oboud presentation ca cx prevention
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Dr abdo oboud presentation ca cx prevention

93

Published on

Published in: Health & Medicine, Technology
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
93
On Slideshare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Abboud Abdo,MD,FRCSC,Gynecologic Oncologist. DhahranHealthCenter SaudiAramcoMedicalServicesOrganisation
  • 2. SiteRisk Allsites1in3 Breast1in7 Lung&bronchus1in17 Colon&rectum1in18 Uterinecorpus1in38 Non-Hodgkinlymphoma1in57 Ovary1in59 Pancreas1in83 Melanoma1in82 Urinarybladder1in91 Uterinecervix1in128 Source:DevCan:ProbabilityofDevelopingorDyingofCancerSoftware,Version5.1StatisticalResearchandApplications Branch,NCI,2003.http://srab.cancer.gov/devcan
  • 3. Primaryprevention:Preventsdiseasefromoccurring. HPVvaccine Secondaryprevention:Detectsandcuresdiseaseinthe asymptomaticphase:PapSmear,HPVtest,Colposcopy Tertiaryprevention:Reducescomplicationsofdisease.
  • 4. WHO2007
  • 5. Cervix  uteri  (Non  Saudis)473.9%2.34.2
  • 6. 0 20 40 60 80 100 120 CervicalCancer:NumberofNewCases1994-­2007
  • 7. PresenceofHumanPapillomaVirus(HPV) LifestyleactivitiesincreasingexposuretoHPV DecreasedImmunocompetency Cofactors:Smoking,OtherSTD Neverbeenscreened,orinadequatelyscreened: 50%ofcervicalcancerpatientsneverhadaPapSmear 10%werenotscreenedwithinthelast5years
  • 8. Detectspre-­invasiveneoplasia Twotechniques,bothacceptable ConventionalPapSmear,fixedonaglassslide. Liquidbased,thinlayerpreparation. Collectionfor HPVtest:highriskserotypes,orgenotypes16/18 OtherSTDs Biopsyanyvisiblelesion
  • 9. Specimentype •ConventionalorLiquidbase Specimenadequacy •Satisfactoryornot Generalcategorisation •NegativeorEpithanomaly Automatedreview •Specifydeviceifaplicable andresult Ancillarytesting •Ifdone;;molecular,HPVand result Interpretation Negative;;Inflam,Endomcell Squamouscellanomaly •ASC,ASC-­US,ASC-­H •LSIL •HSIL •Squamouscellcarcinoma Glandularcellanomaly •Atypical;;Endocerv,Endom •Atypicalfavorneoplastic •Endocervadenoin-­situ(AIS) •Adenocarcinoma Othermalignneoplasms Educationalnotes.
  • 10. 10,000 cancers 300,000HSIL(High-Grade precancerouslesions) 1.25millionLSIL(Low-Grade precancerouslesions) 2-3millionASC(Atypical SquamousLesions) 50-60millionwomenscreened
  • 11. Papscreeningq3years Pap-­RegularPapq3y PapASCUS,HPV-­RegularPapq3y. HPV+Colpo Pap>LSILColpo Co-­testscreeningq5years Pap-­,HPV-­Co-­testq5y PapASCUS,HPV-­Co-­testq5y Pap>LSIL,HPVanyColpo Pap-­,HPV+(2options) 1)Repeatbothin12mo.Ifanypos;;Colpo 2)HPVGenotype16/18.Ifneg;;repeatco-­testin12mo Ifpos;;Colpo
  • 12. Jeddah  Cervical  Screening  Program ww.jcsp.sa.com HR-­‐HPV  testing  and  Reflex  PAP HR-­‐HPV  DNA  in  women  30  +  years  old,        married  more  than  3y Negative Negative Negative Pap  test Positive Positive Colposcopy Positive Repeat  HR-­‐DNA   testing  @  5  year   intervals  till  age  65 Repeat  HR-­‐HPV   testing  at  12   months
  • 13. QUADRIVALENTBIVALENT TargetHPV:16,18,6,11 TrialsFUTURE1&2 RCT:17400patients Efficacy HPVnaïve:98to100% Intentiontotreat:44% 3doses:0,2mo,6mo. AlsoapprovedforAIN andanalcancer TargetHPV16,18 TrialPATRICIA RCT:18000patients Efficacy HPVnaïve:93% Intentiontotreat:30% 3doses:0,1mo,6mo.
  • 14. Intendedforprevention.ItdoesnottreatHPV anddoesnotinterferewithpreexistingdisease. MosteffectiveinHPVnaïvepeople. Ideallybeforesexualexposure Age:Between9yand12y.Catch-­uptill26y. PreviousabnormalPaporHPVdiseaseisnota contraindication,butefficacyisless. Durationofprotection??(>8y) Safety:PreandPostlicensuredata.
  • 15. Preventionisbetterthancure. “Anappleadaykeepsthedoctoraway” Awellappliedprogramofcervicalscreening andHPVvaccinekeepcervicalcanceraway. Becauseitisalmostalwayspreventable,each caseofcervicalcancershouldbeconsidereda failureofthemedicalsystem.

×